Supporting National Prostate Cancer Awareness Month
Mr. Speaker, I rise in strong support of H. Res. 1485, a resolution expressing the support of the House of Representatives for the designation of September 2010, as ``National Prostate Cancer Awareness Month.'' I would like to thank the…
Mr. Speaker, I rise in strong support of H. Res. 1485, a resolution expressing the support of the House of Representatives for the designation of September 2010, as ``National Prostate Cancer Awareness Month.'' I would like to thank the Chairman and Ranking Member of the Energy and Commerce Committee for bringing this important resolution to the Floor. I would also like to thank Representative Randy Neugebauer for his tireless efforts to raise awareness of this terrible disease.
The prostate is a topic that makes all men uncomfortable, present company included. And because of this fact, the disease has become a silent epidemic. According to the latest statistics, 1 in 6 men will be diagnosed with prostate cancer in their lifetime (218,000 men will be diagnosed with prostate cancer this year alone); this rivals the rate of breast cancer in women which is approximately 1 in 8.
That is why we must promote and support Prostate Cancer Awareness Month, to bring this issue into the light, and get men to begin having conversations about their prostate health. It is important for men to take advantage of prostate cancer screening exams in order to detect the disease at the earliest opportunity, when it is still curable.
However, getting more men to pay attention to this issue is only half the battle because a recent study funded by the National Cancer Institute demonstrated that the most common available methods of detecting prostate cancer, the PSA blood test and Digital Rectal Exam, DRE, the only preinvasive indicators available for the detection of prostate cancer, are not particularly adept at detecting prostate cancer. The study showed that many PSA blood tests that screen for prostate cancer result in false-negative reassurances and numerous false-positive alarms (15 percent of men with normal PSA levels still have prostate cancer). Even when PSA levels are abnormal, 88 percent of men end up not having prostate cancer that would require surgery but undergo unnecessary biopsies. As a result more than 1,000,000 U.S. men have prostate biopsies annually--costing our health care system approximately $1.44 billion--many of which could be eliminated if we had advanced diagnostic imaging tools.
When one look at the battle against breast cancer, a disease that again affects about 1 in 8 women, we see that it was a combination of increased awareness along with the development of more sophisticated diagnostic and imaging tools that help improve early detection and survival rates. The same strategy can work for prostate cancer.
For example, preliminary data from a European study demonstrated that when prostate
cancer biopsies were guided by high-precision, experimental MRI, they accurately detected 59% of clinically significant prostate cancer missed by at least two consecutive blind biopsies. Unfortunately, today, neither the U.S. Department of Health and Human Services nor the Department of Defense devotes substantial resources to prostate cancer imaging research. I have been told that the National Institutes of Health spent only $10 million on prostate cancer detection research last year out of a total prostate cancer research budget of $350 million. In short, there is no concerted Federal effort to bring the equivalent of mammography to prostate cancer detection. Representative Cummings and I have introduced legislation, the PRIME Act (H.R. 1485) to correct this problem. The PRIME Act would, among other things, require the National Institutes of Health (NIH), to: (1) carry out a program to expand and intensify research to develop advanced imaging technologies for prostate cancer detection, diagnosis, and treatment comparable to mammogram technology. I encourage my colleagues to co- sponsor this critically importance legislation.
There is still much work to be done if we want to gain the upper hand against a disease that has negatively impacted so many men and their families. Prostate Cancer Awareness Month is a time for us to discuss and confront this epidemic, regardless of how uncomfortable it makes us feel. Despite the fact that men don't like to address these sorts of issues openly, we must acknowledge that the numbers speak for themselves. 32,000 men will die in 2010, 1.5 million men will have invasive and inaccurate biopsies performed, and 70,000 men will have treatment failures while trying to seek help for their condition. These statistics stand as stark reminders of the importance of this month and the dialogue that it will hopefully encourage.
It is my hope that through increased awareness and discussion about prostate cancer, we can begin to chip away at this silent killer. We owe it to ourselves, our fathers, grandfathers, brothers, sons, husbands, and friends to make this effort. I urge my colleagues to support H. Res. 1458.